APLS (Apellis Pharmaceuticals) Other Long Term Assets : $47.5 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Apellis Pharmaceuticals Other Long Term Assets?

Apellis Pharmaceuticals's other long-term assets for the quarter that ended in Sep. 2024 was $47.5 Mil.

Apellis Pharmaceuticals's quarterly other long-term assets increased from Mar. 2024 ($1.3 Mil) to Jun. 2024 ($24.4 Mil) and increased from Jun. 2024 ($24.4 Mil) to Sep. 2024 ($47.5 Mil).

Apellis Pharmaceuticals's annual other long-term assets declined from Dec. 2021 ($31.6 Mil) to Dec. 2022 ($15.8 Mil) and declined from Dec. 2022 ($15.8 Mil) to Dec. 2023 ($1.3 Mil).

Apellis Pharmaceuticals Other Long Term Assets Historical Data

The historical data trend for Apellis Pharmaceuticals's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals Other Long Term Assets Chart

Apellis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

Get a 7-Day Free Trial

0.38

18.86

31.64

15.80

1.31

Apellis Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Long Term Assets	Get a 7-Day Free Trial															1.17	1.31	1.31	24.35	47.53

Apellis Pharmaceuticals Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Apellis Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (NAS:APLS) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

1JK:Germany

Address

100 Fifth Avenue, Waltham, MA, USA, 02451

Website

https://www.apellis.com

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Executives

James George Chopas	officer: See Remarks	950 WINTER STREET, WALTHAM MA 02451
A. Sinclair Dunlop	director	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Pascal Deschatelets	officer: Chief Operating Officer	6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Timothy Eugene Sullivan	officer: Chief Financial Officer	800 BOYLSTON ST., SUITE 3310, PRUDENTIAL TOWER C/O AJU IB INVESTMENT, BOSTON MA 02199
Mark Jeffrey Delong	officer: Senior Vice President	100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Nur Nicholson	officer: Chief Technical Officer	APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Cedric Francois	director, 10 percent owner, officer: Chief Executive Officer	6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Adam J. Townsend	officer: See Remarks	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
David O. Watson	officer: General Counsel	6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Karen Lewis	officer: Chief People Officer	APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Jeffrey Eisele	officer: See Remarks	APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Caroline Baumal	officer: Chief Medical Officer	C/O APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Lukas Scheibler	officer: See Remarks	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Alec Machiels	director	505 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10022
Federico Grossi	officer: See Remarks	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014